Summary:
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Criteria:- Be at least 40 years of age
- Have a BMI of 27kg/m2 or higher
- Have either established cardiovascular disease or cardiovascular risk factors
- NOT have type 1 or type 2 diabetes
- Additional criteria apply
Qualified Participants May Receive:
- Study-related care at no cost
- Compensation up to $1,484 for time and trial-related travel expenses